In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid treatments (ATT) for Alzheimer's disease (AD), revealing a spectrum of opinions across key specialties. With Israel's health system structured to provide universal health care, the high out-of-pocket costs for new AD therapies have raised questions among medical professionals about the feasibility and practicality of implementing these treatments. The study, conducted by Dr.
Noa Bregman and colleagues, is the first in Israel to examine how neurologists, geriatricians, and psychiatrists perceive the new ATT options as they are being introduced into clinical practice. The work appears in the Journal of Alzheimer's Disease . Key findings include: Dr.
Shir noted, "While these innovative treatments offer potential benefits, the findings highlight the importance of addressing the financial and logistical barriers that may hinder broader adoption. Our study underscores the need for multidisciplinary collaboration to ensure comprehensive patient care and to maximize the potential of ATT in Israel." The research team suggests that initiatives aimed at education, cost-benefit analysis , and improved insurance coverage are essential to enhance ATT accessibility and physician confidence.
Establishing specialized AD treatment centers could further support equitable access to these therapies. This study serves as an important step towards understanding and overcoming the chal.
